Genentech/Xoma Raptiva Phase II Psoriatic Arthritis Trial Fails To Show Benefit

The study did not reach statistical significance after 12 weeks of therapy. The preliminary results show that 28% of Raptiva patients achieved an ACR 20 response compared with 19% of patients on placebo.